Skip to main content
Premium Trial:

Request an Annual Quote

Protein, DNA-Analysis Shop Deltadot Raises $10.4M in VC Round

NEW YORK, March 29 (GenomeWeb News) - Deltadot has raised £6 million ($10.4 million) in a round of venture capital financing, the company said today.

 

The company will use the cash to increase production capacity of its recently launched Peregrine and Merlin systems; develop an international sales and marketing force; and help the company develop a protein-folding/-unfolding chip for drug discovery and QA/QC applications, and a "virtual" 2D chip to "replace" 2D gels.

 

Major participants in the financing round included existing investors FF&P Private Equity Limited, which led the round; Imperial Innovations; and NPI Ventures; as well as new investors London Technology Fund and Sitka Health Fund.

 

Deltadot, based in London, develops and sells tools for protein and nucleic-acid analysis through the use of its Label Free Intrinsic Imaging technology, the company said.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.